Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Posted by Brian Himes on Jul 26th, 2026

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 2,004 shares, an increase of 235.7% from the June 30th total of 597 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 10,079 shares, the days-to-cover ratio is presently 0.2 days.

Santen Pharmaceutical Trading Up 0.2%

Shares of SNPHY opened at $11.65 on Friday. The firm’s 50-day moving average price is $12.48 and its 200-day moving average price is $11.52. The firm has a market capitalization of $3.76 billion and a price-to-earnings ratio of 0.10. Santen Pharmaceutical has a 1-year low of $9.22 and a 1-year high of $13.93.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.

View Our Latest Analysis on SNPHY

Santen Pharmaceutical Company Profile

(Get Free Report)

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.